Founded & Funded

Concurrence CEO argues being early equals being wrong in healthcare AI, focusing on infrastructure over point solutions.

19 min Listen to the original Episode page
Healthcare AIStartup StrategyRevenue Cycle ManagementData InfrastructureFDA RegulationPatient Outcomes

Summary

Sabrina Albert interviews Ali Kokar, CEO of Concurrence, about building AI infrastructure for healthcare that learns from every patient interaction. Kokar asserts that being too early in a high-stakes industry is functionally equivalent to being wrong, necessitating a balance of short-term value and long-term vision. He distinguishes Concurrence's 'super intelligent care' from 'medical superintelligence,' emphasizing systems that support rather than replace providers. The company deliberately avoids lucrative but narrow point solutions like Revenue Cycle Management to focus on foundational infrastructure. Kokar highlights that healthcare's lack of longitudinal context, not data volume, hinders care improvement, and AI can capture this through agentic workflows.

Episode sections

  1. 0:00 – 1:49

    Introduction and Vision

    Sabrina Albert introduces Ali Kokar, CEO of Concurrence, to discuss the company's goal of helping healthcare organizations learn from every patient. The segment outlines the episode's focus on building companies before all pieces are in place, distinguishing between being early versus wrong, and earning trust in a skeptical market.

  2. 1:49 – 3:41

    Causal Understanding and Medical Superintelligence

    Kokar explains that Concurrence aims to build a causal understanding of human health, moving beyond billing-anchored records to capture richer context at the line of care. He distinguishes Concurrence's approach from 'medical superintelligence' by preferring 'super intelligent care,' which focuses on continuously learning systems that support providers rather than replacing them.

  3. 3:41 – 4:59

    Health World Model and Agentic Workflows

    Concurrence builds a unified 'health world model' for health systems and creates bespoke agentic workflows across the patient journey. These workflows support pre-visit intake, the visit itself, and post-visit tasks like specialist referrals, medication adherence, and side effect management.

  4. 4:59 – 6:27

    Being Early vs. Being Wrong

    Kokar asserts that being too early is essentially the same as being wrong. He identifies three conditions making the future of AI in healthcare inevitable: a mindset shift toward new technology, regulatory openness from the FDA, and continuous improvements in foundational models. He emphasizes delivering short-term value while building toward this long-term state.

  5. 6:27 – 8:41

    Avoiding Small Poisonous Ponds

    Kokar warns against the conventional startup advice of going super narrow in healthcare, calling it a 'small poisonous pond.' He argues that patient outcomes require addressing multiple touchpoints across different industries and workflows. Instead, Concurrence focuses on foundational infrastructure and safety reliability to drive value across the entire ecosystem.

  6. 8:41 – 9:49

    Passing on RCM and Lucrative Wedges

    Concurrence deliberately passed on Revenue Cycle Management (RCM) and other lucrative point solutions like prior authorization and ambient listening. Kokar states that while these offer clear short-term ROI, they distract from the core mission of driving patient outcomes and can complicate long-term product strategy.

  7. 9:49 – 11:43

    Overcoming Skepticism and Data Integration

    Kokar notes that healthcare customers are skeptical by design and trust must be deeply earned. To overcome this, Concurrence integrates directly into existing governed environments like Databricks, Azure, or Snowflake, allowing health systems to use their current infrastructure without migrating data or rebuilding platforms.

  8. 11:43 – 19:09

    The Gap in Data Collection and AI's Role

    Despite generating vast amounts of data, healthcare has not improved care because it lacks rich, longitudinal context. AI enables systems to sit at the line of care, capturing net-new information through conversations and follow-ups that explain why treatments succeed or fail, which traditional snapshots miss.

Claims worth verifying

Concurrence was previously called Amigo.

Unidentified speaker ·16:07

How to verify: Check the company's press releases or website history for the name change announcement.

Dr. Jay Shaw is the Chief Medical Officer at Concurrence and was previously the chief of physician staff at Stanford Health.

Unidentified speaker ·16:37

How to verify: Verify via LinkedIn profile of Dr. Jay Shaw or Concurrence's leadership page.

Heithum previously worked as a lead and director at the NIH before joining Concurrence.

Unidentified speaker ·16:48

How to verify: Verify via LinkedIn profile of Heithum or Concurrence's leadership page.

Concurrence is deployed in seven different countries.

Unidentified speaker ·14:18

How to verify: Check Concurrence's case studies, press releases, or official website for deployment statistics.

Concurrence has conducted over 10 million patient conversations or encounters in its medication side effect management workflow.

Unidentified speaker ·14:28

How to verify: Verify via Concurrence's published metrics, case studies, or press releases detailing usage statistics.

Medication adherence increased almost 3x in scenarios where patients actively engaged with Concurrence's systems.

Unidentified speaker ·14:43

How to verify: Verify via Concurrence's published study results, case studies, or white papers on medication adherence outcomes.

A study with a customer found that almost 60% of durable knowledge about patients was learned through conversations rather than devices or blood tests.

Unidentified speaker ·15:10

How to verify: Verify via Concurrence's published research, case studies, or technical reports on data sources for patient insights.

The FDA is more open and comfortable with AI systems sitting at the line of care.

Unidentified speaker ·5:31

How to verify: Review FDA guidance documents, press releases, or regulatory announcements regarding AI in healthcare during the period discussed.

Concurrence integrates with Databricks, Azure, and Snowflake.

Unidentified speaker ·11:02

How to verify: Check Concurrence's technical documentation, partnership announcements, or website for supported integrations.

Sabrina Albert is a partner at Madrona.

Unidentified speaker ·0:41

How to verify: Verify via Madrona's website team page or LinkedIn profile of Sabrina Albert.

Do your own research

  • Verify FDA regulatory guidance documents regarding AI systems operating at the line of care to assess Kokar's claim of 'regulatory openness.'
  • Review Concurrence's public case studies or whitepapers to verify the specific 3x increase in medication adherence metrics.
  • Check Databricks, Azure, and Snowflake partnership announcements or technical documentation to confirm Concurrence's integration capabilities.
  • Analyze the competitive landscape for 'health world models' to assess if Concurrence's infrastructure approach is defensible against narrow point solutions.
  • Research healthcare provider skepticism surveys to validate the claim that trust must be 'deeply earned' and data migration is a major barrier.
  • Look for independent analyses of Revenue Cycle Management (RCM) market growth to evaluate the opportunity cost of Concurrence's strategic pivot.
  • Examine recent improvements in foundational model capabilities to assess the validity of Kokar's prediction about continuous AI advancement.
  • Investigate Concurrence's funding history and investor relations materials to understand the financial pressure to deliver short-term ROI versus long-term vision.
Full transcriptexpand
0:00
Unidentified speaker: We're gonna see health systems that are continuously learning from every act of care that they're delivering.
0:04
Unidentified speaker: And then for that patient, the dream of end state precision care is finally going to be real.
0:09
Unidentified speaker: The feeling of hundreds of providers who are constantly sitting there, making sure that they know everything about you to give you the best care possible is a dream that will finally be true.
0:18
Unidentified speaker: As a founder, the thing I think about always is like being too early is essentially the same as being wrong.
0:22
Unidentified speaker: Customers in this space should be skeptical.
0:24
Unidentified speaker: Skepticism is good.
0:26
Unidentified speaker: There's a lot of players saying a lot of different things.
0:28
Unidentified speaker: Trust has to be quite deeply earned in this space, especially in the context of when you're ever engaging with patients.
0:39
Unidentified speaker: Welcome to Founded and Funded.
0:41
Unidentified speaker: I'm Adrena partner Sabrina Albert, and today I'm here with Ali Kokar, co-founder and CEO of Concurrence.
0:47
Unidentified speaker: In this episode, we dig into Concurrence's goal of helping healthcare organizations learn from every patient they treat.
0:54
Unidentified speaker: Why that's been so difficult despite decades of medical data and what breakthroughs Ollie believes could finally make this possible.
1:00
Unidentified speaker: We also talk about how to build a company before all the pieces are in place, how to tell whether you're early or wrong, which opportunities to pass up, and how to earn the trust of healthcare customers who are skeptical by design.
1:12
Unidentified speaker: With that, let's dive in.
1:14
Unidentified speaker: Thanks for being here, Ollie.
1:16
Unidentified speaker: Thank you.
1:17
Unidentified speaker: Excellent to be here.
1:18
Unidentified speaker: In an era of unprecedented innovation, uh plenty of founders are building for capabilities that don't yet exist.
1:24
Unidentified speaker: You're doing it in the health and medical sector where the stakes are huge and historically the buyers have been slower.
1:30
Unidentified speaker: So despite all the tech and data that's out there, healthcare companies are not learning from the patients they treat.
1:36
Unidentified speaker: I think this is a this is a problem that would sound pretty straightforward to solve, but it's been a very persistent problem over the last many decades.
1:44
Unidentified speaker: Maybe we start by understanding what is it that you're building today that wasn't possible before, and why are you sure it will be?
1:49
Unidentified speaker: The way I think about it is at concurrence, we're trying to build a causal understanding of human health.
1:56
Unidentified speaker: Historically, this has never been possible, especially because inside of a patient record or a patient summary, all it is is really summarizing what that visit was, especially because it's very anchored around billing and compliance.
2:07
Unidentified speaker: It's not really anchored around driving patient outcomes.
2:10
Unidentified speaker: Now, for the first time, you have this new technology that is actually able to sit in the line of care delivery and capture a lot more richer understanding and context about a patient.
2:21
Unidentified speaker: That really rich understanding then allows you for the first time get a good sense of what is actually driving certain outcomes.
2:28
Unidentified speaker: And so, because of this sort of core technical breakthrough, for the first time, we're able to capture net new information, make sense of it in a way that was never possible before, and as a result, sort of understand how to drive certain outcomes.
2:42
Unidentified speaker: And I've heard in the market this this term called medical superintelligence.
2:45
Unidentified speaker: Is that a different way than you're thinking about it?
2:48
Unidentified speaker: This idea of causal understanding, maybe unpack that a little bit more for us.
2:52
Unidentified speaker: When most people think of this term medical superintelligence, which is very loaded, right?
2:56
Unidentified speaker: You usually think of this monolithic system that is superhuman and better than any doctor, any provider.
3:02
Unidentified speaker: We don't actually necessarily think of it that way.
3:04
Unidentified speaker: We think of it as more of a continuously learning system that is really focused on understanding what is driving certain outcomes and then being able to actually deliver that care in a meaningful way.
3:16
Unidentified speaker: And in some cases, that might mean actually helping those providers deliver that superhuman care.
3:20
Unidentified speaker: We actually prefer the term super intelligent care versus medical superintelligence because it's more around the system that is continuously learning, continuously evolving, where you have a really rich understanding of every single patient to then actually deliver that end care.
3:34
Unidentified speaker: Okay, so taking a step back, what does this actually mean for health systems and providers that you're working with and how can they actually deliver tangible care?
3:41
Unidentified speaker: So, what we usually do when we start working with some of these larger health systems is one, build this unified understanding of their entire ecosystem with a very patient-centric view.
3:50
Unidentified speaker: We call this sort of the health world model.
3:52
Unidentified speaker: And then on top of that, we work with them to build very bespoke, very custom patient-facing or provider-facing agentic workflows.
4:00
Unidentified speaker: So you can think a patient is coming into a visit.
4:02
Unidentified speaker: Before a visit, there's a bunch of things that need to happen.
4:04
Unidentified speaker: They need to make sure their appointment is booked.
4:06
Unidentified speaker: We do intake, triage, and so on and so forth.
4:08
Unidentified speaker: The visit itself is really rich, important piece of context that we want to capture and support and give a lot of information to that provider.
4:15
Unidentified speaker: And then after that visit, everything that takes place from making sure that they're actually going, if they were referred to a specialist, that they actually go have that appointment booked, they can actually show up.
4:24
Unidentified speaker: If they're a prescribed medication, side effect management is a big piece.
4:28
Unidentified speaker: Medication adherence is a big piece.
4:30
Unidentified speaker: So a lot of our sort of focused solutions end up being across that patient journey and sitting in the line of care delivery, but very often supporting that health system across the board.
4:41
Unidentified speaker: So we talked about your framing of this idea of super intelligent care.
4:44
Unidentified speaker: And when the conditions are finally right, I think they unlock a series of breakthroughs that can make an idea seem almost inevitable.
4:51
Unidentified speaker: And I'm curious, what is the founder's job in all of this?
4:54
Unidentified speaker: And how do you tell from being early versus being wrong?
4:58
Unidentified speaker: And what would you watch out for?
4:59
Unidentified speaker: As a founder, the the thing I think about always is like being too early is essentially the same as being wrong.
5:05
Unidentified speaker: And so we started thinking through what are the right sort of conditions in this space right now that allow us to have the belief that this end state is going to be inevitable and a reality and that we should start building towards it.
5:17
Unidentified speaker: Um, but at the same time, then what are we doing today tangibly to continuously sort of build towards that future?
5:22
Unidentified speaker: At the macro level, you can think of it as a massive industry mindset shift around adopting net new technology.
5:28
Unidentified speaker: That's for sure the case in healthcare.
5:30
Unidentified speaker: The regulatory environment is changing.
5:31
Unidentified speaker: The FDA is way more open and comfortable with a lot of these AI systems being and sitting at the line of care, helping drive patient outcomes.
5:39
Unidentified speaker: There's obviously technology breakthroughs.
5:42
Unidentified speaker: These foundational models are continuously getting better and better.
5:44
Unidentified speaker: They still need the right system and orchestration around them.
5:47
Unidentified speaker: And that's where we've focused a lot of our energy on.
5:49
Unidentified speaker: But most importantly, there's this thought around okay, can we actually deliver value today to that end patient, to that health system?
5:57
Unidentified speaker: And that's very clearly yes, through a lot of the use cases, like I mentioned, across that patient journey, while also having and building this foundation towards this end state future that is almost inevitable.
6:08
Unidentified speaker: And so we sort of think of it as making sure that there's short-term value being delivered and the product that we're building is very intentionally built so that that superintelligent care world is inevitable for us.
6:18
Unidentified speaker: And as you situate yourself for this future playing field, we talked a little bit early about avoiding small, poisonous ponds.
6:25
Unidentified speaker: What does that mean when you put it into practice?
6:27
Unidentified speaker: Yeah, I think um a lot of founders, especially in healthcare, fall into this trap.
6:31
Unidentified speaker: Uh, maybe I'll help define it a little bit.
6:33
Unidentified speaker: The way I think about it is there's a lot of sort of like very narrow ponds we could we think of them inside in in the context of healthcare where folks are building companies.
6:42
Unidentified speaker: And so a lot of my founder friends have said, okay, let's pick one sort of very specific industry, one specific vertical, orthopedics, dental, behavioral health, whatever the case may be.
6:52
Unidentified speaker: Let's then pick one specific workflow and just build a product and company around automating that.
6:57
Unidentified speaker: Now, that is actually like standard conventional startup advice, is like go super narrow and super deep on a specific problem.
7:03
Unidentified speaker: I think the challenge for why it does not work in healthcare is that as soon as you go into that, you'll start realizing that to actually drive end patient outcomes and sort of deliver a lot of value, you need to touch many different problems across that patient journey, across even many different industries, right?
7:20
Unidentified speaker: Because you think of it as a patient, you're not actually saying, oh, cool, I want to go and do sort of like therapy at this provider specifically.
7:28
Unidentified speaker: Then you're also going to emerge and then you're also going to your PCP.
7:31
Unidentified speaker: And that same patient is having sort of various touch points with the healthcare industry.
7:35
Unidentified speaker: Companies who are then saying, I'm just going to automate this, end up getting stuck because you then have all these other problems in terms of retaining context, supporting that patient across various aspects of that journey inside of that ecosystem, inside of that health organization, but then also beyond.
7:53
Unidentified speaker: And so we then say, okay, building in that very narrow way, we think of it as sort of this small poisonous pond almost where you go in there with the right initial mindset around conventional startup wisdom, but then you get caught.
8:04
Unidentified speaker: And so we took the approach of if we just zoom out and look at the entire industry as a whole, what are the foundational building blocks we should be building from an infrastructure standpoint, from a safety reliability standpoint, from a understanding of patient across their entire life standpoint that then can really, really drive lots of value and impact.
8:21
Unidentified speaker: And so that's sort of one thing that we always think about is how do we make sure we're not sort of falling into that trap?
8:26
Unidentified speaker: Okay.
8:26
Unidentified speaker: So tell us about a pod that you deliberately walked past.
8:29
Unidentified speaker: It's obviously hard sometimes in the moment to walk past these things when you think that there's a really big opportunity ahead of you.
8:35
Unidentified speaker: And but as a founder, it's your job to think about prioritization of these things.
8:38
Unidentified speaker: What did it cost you and how do you think about the trade-offs?
8:41
Unidentified speaker: Oh my God, a lot.
8:42
Unidentified speaker: We've uh had to make some very tough decisions around how we've defined our product and platform strategy, which opportunities we've said no to.
8:50
Unidentified speaker: Like an obvious example is RCM, right?
8:52
Unidentified speaker: Everybody in the industry, all of my founder friends often just say, just go to RCM, that's where a lot of the money's at.
8:57
Unidentified speaker: Just go focus your energy on that.
8:59
Unidentified speaker: The ROI is clear and so on and so forth.
9:01
Unidentified speaker: And that's fair and that's true.
9:03
Unidentified speaker: However, we wanted to really, really focus a lot of our energy on what does it actually mean to deliver care?
9:08
Unidentified speaker: What does it actually mean to drive those outcomes?
9:10
Unidentified speaker: And sort of being and sitting at the point of Rev Cycle Management or Prioroth or even ambient listening, all of these sort of point solutions make sense and can be very lucrative in the short term, but in the long term, can cause a lot of challenges around how you think about then your product strategy, how you think about what you're trying to build, who you're selling to, and so on and so forth.
9:30
Unidentified speaker: Um, and so it's a lot of opportunity costs that we say no to early on, but it is already paying us quite a bit of dividends.
9:37
Unidentified speaker: I think one of the reasons people do focus on these, you know, wedges as you were describing it, is because healthcare as a industry has historically been more skeptical by design and they want to see the ROI, the product right away.
9:49
Unidentified speaker: Um, but what are you learning as you're building at this infrastructure layer of why customers are saying yes to you?
9:55
Unidentified speaker: And and I know you guys just announced a big partnership with Databricks as well.
9:59
Unidentified speaker: Um, so maybe share a little bit about how how you make it easy for the customers in a historically skeptical world to say yes.
10:05
Unidentified speaker: Yeah, I always say customers in this in this space should be skeptical.
10:09
Unidentified speaker: Um, skepticism is good.
10:10
Unidentified speaker: There's a lot of players in this space saying a lot of different things.
10:14
Unidentified speaker: Um so we actually love working with folks who are quite skeptical.
10:17
Unidentified speaker: Um, the way we think about it is like trust has to be quite deeply earned in this space, earned especially in the context of when you're ever engaging with patients in any way, shape, or form.
10:27
Unidentified speaker: And so we think of that whether it's in the context of safety or reliability or how we train of our all of our systems, how all of our customers are part of that equation.
10:35
Unidentified speaker: So they get to really shape it and really understand how these systems are going to behave.
10:40
Unidentified speaker: I think in the in the context of what we're building, having an understanding of sort of a true longitudinal patient record is really important.
10:47
Unidentified speaker: That means having access to data that is super sensitive.
10:50
Unidentified speaker: That means talking and spending a lot of time with compliance and legal teams.
10:53
Unidentified speaker: And that's all great.
10:54
Unidentified speaker: We should be doing that.
10:55
Unidentified speaker: And so, in an effort to try to make some of those things really easy, we'll come to you wherever your entire ecosystem is built.
11:02
Unidentified speaker: Whether you're on a Databricks, whether you're on an Azure or a Snowflake, whatever the case may be, we'll come in and work inside of your existing governed governed environments and really help accelerate your journey that you've taken already.
11:13
Unidentified speaker: Um, that really helped us overcome the second batch of skepticism around do I have to completely redo my entire business from scratch in order to work with you?
11:21
Unidentified speaker: And the answer is no, of course not.
11:22
Unidentified speaker: Yeah.
11:22
Unidentified speaker: And these companies have already invested so much in building out their, their, their platform of choice, be that with Databricks and the cloud partners.
11:30
Unidentified speaker: And they don't want to make that transition out.
11:31
Unidentified speaker: They don't want to pull out their data.
11:32
Unidentified speaker: So if you can be at that layer in what you're partnering with them, um, it allows for you to have an opportunity with them.
11:39
Unidentified speaker: As a patient, I'm familiar with my epic system, my chart, et cetera.
11:43
Unidentified speaker: And healthcare as a hist as a segment has historically generated more data than a lot of industries out there.
11:49
Unidentified speaker: Um, but it hasn't made care better.
11:51
Unidentified speaker: And I'm curious why, why do you think that is?
11:54
Unidentified speaker: And what does AI actually make possible for the first time?
11:56
Unidentified speaker: Yeah, I think um the way I think about it is it's it's twofold.
11:59
Unidentified speaker: One is we're not uh collecting enough understanding and information, right?
12:04
Unidentified speaker: Like I mentioned, we're seeing a patient will go in and see their PCP maybe once or twice a year.
12:09
Unidentified speaker: And really, that's the point-in-time snapshot of understanding that we now have captured.
12:13
Unidentified speaker: And so AI for the first time allows us to sit at the line of care and actually capture way more information and the right type of information is both at the same time, right?
12:24
Unidentified speaker: So, like let's go very specific.
12:26
Unidentified speaker: You're a patient, you came in, you got some medication, and you went home.
12:30
Unidentified speaker: And now we don't actually know are you if if this medication is working or not.
12:34
Unidentified speaker: And if it's not working, is it just because it's the wrong medication, it's the wrong dosage, or is it because something happened in your life that you stopped taking it altogether?
12:41
Unidentified speaker: Right?
12:42
Unidentified speaker: All of that really rich understanding is completely missing.
12:45
Unidentified speaker: We need that understanding to actually build this causal understanding of human health.
12:49
Unidentified speaker: And so for the first time now, these systems, if built safely and reliably, in the way that we've been focusing a lot of our efforts on, can actually safely sit at the line of care, communicate with you, follow up with you, understand why or why not you may or may not be taking some medication in this example, and then connect the dots back inside of that existing system and epic or whatever the case may be, so that that provider has a holistic, full understanding of what to do next in the context of your care.
13:16
Unidentified speaker: And so it's both a matter of we're not collecting enough rich context and data about that patient, nor is it the right type.
13:23
Unidentified speaker: Once all of a sudden you have this technology, you can do both of those.
13:27
Unidentified speaker: And then you're now collecting way more understanding and information than ever before.
13:31
Unidentified speaker: Luckily, these foundation models, actually, if you think of them as a search primitive, are phenomenal at looking at a really large amount of data and finding causal patterns and starting to think through, okay, how what is actually driving certain outcomes?
13:45
Unidentified speaker: And so it sort of ends up being twofold in that way.
13:48
Unidentified speaker: Can you walk through an example of one of your customers and how they actually leverage um concurrence today and what that actually looks like and how and and how you're actually getting a lot of that data?
13:57
Unidentified speaker: Because you're powering a lot of these conversations, as you talked about before, be that kind of in the pre-visit workflows, but often in the traditional visit workflow.
14:04
Unidentified speaker: So actually having a conversation with the system itself.
14:08
Unidentified speaker: And then post post-visit, how do you do the right, you know, adherence, follow-ups, et cetera?
14:14
Unidentified speaker: Yeah, happy to do so.
14:15
Unidentified speaker: I'll give you one concrete example.
14:16
Unidentified speaker: Uh, we have an organization that's fairly global.
14:18
Unidentified speaker: Um, we're deployed in seven different countries, and we're specifically in the workflow of post-prescription of a medication, doing side effect management and health coaching.
14:28
Unidentified speaker: Um, and so in that case, we've done 10 million plus conversations or patient encounters there.
14:34
Unidentified speaker: And we've found that we've actually, through our systems, been able to drive up medadherence, almost 3x in scenarios where those patients are actively engaging.
14:43
Unidentified speaker: And when that patient then, when we do escalate, when there is some urgent situation that shouldn't be handled by our systems, that provider now has way richer understanding and context of hey, here's actually what's been going on with Sabrina over the last few weeks, here's why she needs to come in for a visit.
14:58
Unidentified speaker: We've booked her in, but here's a really rich context of what's been going on in her life.
15:02
Unidentified speaker: And so that becomes really, really important.
15:04
Unidentified speaker: And then we went back and sort of did a study with them to understand how are we causing a lot of really under good understanding of patients?
15:10
Unidentified speaker: We build these digital twins, and we found that almost 60% of the durable knowledge and information and context about each patient was learned not from their devices, their biometric markers, their blood tests, their visits, but actually just through the conversations that we were having.
15:27
Unidentified speaker: And so, like it really proved out to us that the when you can put these agents safely, reliably in the line of care, you can collect net new context that then is so durable and helps inform the care of that individual.
15:40
Unidentified speaker: And we can sort of share a lot of that information with that entire care team, whether it's their PCP, whether it's a specialist they're being referred to, whether it's the nurse or care coordinator who's calling them after the fact or whatever the case may be.
15:52
Unidentified speaker: And over time, then the patient's experience gets much better because it's more bespoke to them, the different individuals.
15:58
Unidentified speaker: And you're able to extract a lot of that data from existing systems, but then you're also able to pair it with this model that's improving, improving over time.
16:06
Unidentified speaker: Precisely.
16:06
Unidentified speaker: Exactly.
16:06
Unidentified speaker: That's awesome.
16:07
Unidentified speaker: So I want to um, you know, when we first met, uh, I guess it's been over a year now, the company was actually called Amigo, and you guys recently expanded um in a lot of ways, and the company is now called Concurrence.
16:20
Unidentified speaker: Um, I'm curious what was the thesis behind doing that?
16:23
Unidentified speaker: The name is obviously the visible part, but what else has changed?
16:26
Unidentified speaker: Yeah, the name was actually the very last thing to change.
16:28
Unidentified speaker: Uh, for over the last year, we've really been reorienting the company around our expanded mission.
16:32
Unidentified speaker: That means the type of talent and people that we hired.
16:36
Unidentified speaker: So we brought over Dr.
16:37
Unidentified speaker: Jay Shaw, who's the chief of physician staff at Stanford Health before, to be our chief medical officer.
16:42
Unidentified speaker: We brought over Heithum, who was previously a lead and director at the NIH, to come in and lead a lot of our deployment function.
16:48
Unidentified speaker: And so the way we've been thinking about the talent and the people at this company has been very much a big shift.
16:55
Unidentified speaker: And then also, I would say the types of customers that we work with and serve.
16:58
Unidentified speaker: So we've had some really, really amazing conversations and paths ongoing with some large governments abroad, uh, large health systems, one of the largest pharma companies in the world, who all want to sort of go and influence and impact how care is delivered.
17:11
Unidentified speaker: And so that's sort of also been another really exciting piece that we'll share more about soon.
17:15
Unidentified speaker: But the name is the is the very last part.
17:17
Unidentified speaker: Now, what doesn't change is really a lot of our focus and emphasis that has been since we first met around safety evaluation, like what are the rigorous testing we do before any of these systems are allowed to go out and be deployed into the world.
17:31
Unidentified speaker: Um, and and going back to sort of areas that we don't necessarily focus on, i.e.
17:36
Unidentified speaker: just helping monetization, but rather focused very heavily on patient-facing care delivery.
17:40
Unidentified speaker: Yeah, I think safety, patient trust in this, in this vertical, this industry is one of the most important things and cannot be um undermined in any way.
17:49
Unidentified speaker: So I love that about your guy, your guys' focus and the thesis um has always resonated with me.
17:55
Unidentified speaker: And so as we think five years out, what is different for patients and providers?
17:59
Unidentified speaker: And what do you think will have to happen for that to be true?
18:02
Unidentified speaker: On the health system side more broadly, we're gonna see health systems that are continuously learning from every act of care that they're delivering.
18:08
Unidentified speaker: They're able to get way more understanding of what's happening inside of their ecosystem and be able to really, really deliver good care at a lower cost of that care.
18:16
Unidentified speaker: On the provider side specifically, we're going to be able to equip them for the first time ever, a really holistic causal understanding of what is happening inside of a patient's life, what is driving certain outcomes, and how they can deliver the best care to that end patient.
18:32
Unidentified speaker: And then for that patient, the dream of end state precision care is finally going to be real.
18:39
Unidentified speaker: Really, the feeling of hundreds of providers who are constantly sitting there, making sure that they know everything about you to give you the best care possible is a dream that will finally be true.
18:48
Unidentified speaker: I'm excited for that future state.
18:50
Unidentified speaker: I think with that, with the tech and what you guys are building at concurrence, we can actually get there, which is a big reason that you know Madrona is excited to be an investor in you guys from day one.
18:59
Unidentified speaker: And as a as a patient, I'm hoping I'm hopeful for that um experience uh as well.
19:03
Unidentified speaker: So thanks very much, Ollie, for being here with us today.
19:06
Unidentified speaker: This was a lot of fun.
19:07
Unidentified speaker: Of course.
19:07
Unidentified speaker: Thank you for having me.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3 and interpreted by Qwen3.6-35B-A3B-GGUF:UD-Q4_K_XL. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights